Nuheara Limited (NUH.AX)
| Previous close | 0.1700 |
| Open | 0.1700 |
| Bid | 0.1650 x 197574900 |
| Ask | 0.1700 x 26031200 |
| Day's range | 0.1650 - 0.1700 |
| 52-week range | 0.1400 - 1.0400 |
| Volume | |
| Avg. volume | 155,765 |
| Market cap | 17.048M |
| Beta (5Y monthly) | 1.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Nuheara Announces New US-Based CEO and Engagement of Roth Capital Partners to Explore US Listing
BELLEVUE, Wash., May 09, 2022 (GLOBE NEWSWIRE) -- Medical device manufacturer, Nuheara Limited (ASX:NUH) (Company or Nuheara) is pleased to announce a series of structural changes designed to advance the Company’s unique and growing US based hearing healthcare market opportunities: The appointment of John R. Luna as its global, US based, Chief Executive Officer;Co-founder and former CEO, Justin Miller, remaining as the Company’s Managing Director;Engagement of Roth Capital Partners LLC (“Roth”)
- GlobeNewswire
Nuheara Submits 510(k) for U.S. FDA Clearance
BELLEVUE, Wash., April 12, 2022 (GLOBE NEWSWIRE) -- Nuheara Limited (ASX:NUH) (Company or Nuheara) has taken the final step in its plans to secure U.S. Food and Drug Administration (FDA) clearance for its self-fitting hearing aid by providing its 510(k) submission to the FDA. This follows completion of Nuheara’s successful clinical trial by National Acoustic Laboratories (NAL) in January 2022. The trial successfully validated the effectiveness of the Nuheara self-fitted hearing aids compared to
- GlobeNewswire
Nuheara Welcomes Landmark FDA Proposed Rules for Over-the-Counter Hearing Aids
Nuheara is already undertaking clinical trials of a self-fit hearing aid and plans to file a 510(k) to launch one of the first products availableSAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nuheara (ASX: NUH), the developer of smart and affordable hearing solutions that transform the way people hear, welcomes the U.S. Food and Drug Administration (FDA) issuing its landmark proposal intended to improve access to and reduce the cost of hearing aid technology for millions of Americans[1]. The U
